In an interview with The Data Economy CXO podcast, Bülent Kiziltan, Head of Causal and Predictive Analytics at Novartis' AI and innovation lab, discusses the company's mission to improve drug development efficiencies using data, analytics, industry partnerships, and diverse talent. The goal is to shorten the period for drug development and discovery by creating additional evidence through data science methodologies. Novartis has been transforming into a data science company over several years, with its AI innovation lab focusing on causal and predictive analytics, natural language processing, and image analytics. Kiziltan emphasizes the importance of investing in both R&D-driven core capabilities and real-world impact strategies for sustainable value creation from data science and AI.